NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cellectis S.A. (CLLS) Stock Analysis

Cellectis S.A. (CLLS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CLLS

$0.97

−$0.02 (−2.17%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLLS with… →

CLLS Key Statistics

As of Oct 21, 2026
Trading
Open
$1.07
Previous Close
$0.99
Day's Range
0.91–1.08
52-Week Range
1.09–5.48
Volume
282.09K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.91
Valuation
Market Cap
$110.81M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.70
Financials (FY)
Revenue (FY)
$72.95M+75.76%
Net Income (FY)
−$67.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
−102.34%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.73M
1-Year Return
−73.68%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
82.71K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CLLS closed at $0.97, −73.68% over 1 year.

Cellectis S.A. (CLLS) has a market capitalization of $110.81M.

In fiscal 2025, CLLS reported revenue of $72.95M.

CLLS Stock Return by Calendar Year

Cellectis S.A. (CLLS) 10-year return: what $10,000 became

1 year
$10,000 $2,632
−73.68%
5 years
$10,000 $862
−91.38%
10 years
$10,000 $510
−94.90%

If you had invested $10,000 in Cellectis S.A. (CLLS) 10 years ago, at the close on October 21, 2016, it would have been worth $510 at the close on October 21, 2026: −94.90% in total, −25.74% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−79.99%
2025+168.89%
2024−41.56%
2023+46.67%
2022−74.14%
2021−69.99%
2020+58.06%
2019+2.82%
2018−42.88%
2017+71.98%
2016 (partial year)−38.94%

As of October 21, 2026.

CLLS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.95M−$67.59M−92.7%
2024$41.51M−$36.76M−88.6%
2023$755.00K−$101.06M−13,385.3%
2022$19.17M−$106.14M−553.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.95M$63.15M−$33.08M−$67.59M−92.7%
2024$41.51M$32.32M−$59.55M−$36.76M−88.6%
2023$755.00K−$6.66M−$97.30M−$101.06M−13,385.3%
2022$19.17M$10.69M−$89.67M−$106.14M−553.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLLS Valuation vs Biotechnology Median

Median of 608 stocks
MetricCLLSBiotechnology medianvs median
P/S ratio1.7413.300.1x the median
Profit margin−102.34%−38.31%64.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cellectis S.A. (CLLS) carries a market capitalisation of $110.81M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 224.

Over the past 52 weeks the price has ranged from $1.09 to $5.48. The most recent close on file for CLLS is $0.97, dated October 21, 2026. That is −$0.02 (−2.17%) against the previous close.

Financial Health

Fiscal 2025 revenue came to $72.95M. Against the prior fiscal year total of $41.51M, that is a change of +75.76%. The same year closed with a net loss of $67.59M. Profit margin runs at −102.34%. That is 64 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.7.

Across the 4 fiscal years on file, revenue moves from $19.17M in 2022 to $72.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.74. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −73.68%. Measured over 10 years, that is −25.74% a year compounded. Beta against the wider market is reported at 2.91. Annualized volatility over the trailing 10 years is 90.81%.

Growth & Income

The record shows no dividend for CLLS.

2026 is still running; the total return is −79.99% year to date. The strongest complete calendar year on file is 2025 at +168.89%; the weakest is 2022 at −74.14%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Cellectis S.A. (CLLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cellectis S.A. CLLS $110.81M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cellectis S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Visit website →